Ulipristal Acetate: A Review in Symptomatic Uterine Fibroids

@article{Garnockjones2017UlipristalAA,
  title={Ulipristal Acetate: A Review in Symptomatic Uterine Fibroids},
  author={Karly P Garnock-jones and Sean T. Duggan},
  journal={Drugs},
  year={2017},
  volume={77},
  pages={1665-1675}
}
Oral ulipristal acetate (Esmya®; Fibristal®), a synthetic selective progesterone receptor modulator, is the first selective progesterone modulator to be approved for the treatment of uterine fibroids. It was initially approved for the preoperative treatment of moderate to severe uterine fibroid symptoms in women of reproductive age. Recently, the indication was extended in the EU to include the intermittent treatment of moderate to severe uterine fibroid symptoms. This narrative review… Expand
Management of symptomatic uterine fibroids with ulipristal acetate: a retrospective, multicentric and nationwide study.
TLDR
The data confirm favorable outcomes after UPA therapy for women of childbearing age and premenopausal in Portugal and are in line with published literature. Expand
Fibroids and Infertility
TLDR
There are multiple options for the treatment of fibroids; however, patients who are candidates for expectant, medical or surgical management should be individualized, and especially if they are going to be taken to surgery, an excellent mapping of Fibroids prior to surgical intervention is recommended. Expand
Hysteroscopic and ultrasonographic evaluation of ulipristal acetate treatment for symptomatic myomas in premenopausal women: a prospective study.
TLDR
UPA is a safe, effective and assured method to decrease symptoms, reduce the need for surgery in premenopausal women suitable for the treatment. Expand
Extractive Spectrophotometric Determination of Ulipristal Acetate using Naphthol Blue Black
Ulipristal acetate is used to treat uterine fibroids and for emergency birth control. The present study is a first report on development of a visible spectrophotometric method for determination ofExpand
The Usefulness of Immunohistochemistry in the Differential Diagnosis of Lesions Originating from the Myometrium
TLDR
The current state of knowledge about the use of immunohistochemical markers in the differential diagnosis of LM, atypical LM, smooth muscle tumors of uncertain malignant potential (STUMP), and LMS is presented, as well as their clinical predictive value. Expand
Single-port laparoscopic myomectomy in the virgin womb - a retrospective analysis of 31 consecutive cases
TLDR
The feasibility of single-port laparoscopic myomectomy in the virgin womb with a retrospective chart review of 31 consecutive cases performed by a single surgeon was evaluated, and there were differences in blood loss and operation time based on the maximum diameter of myoma. Expand
Ulipristal acetate determination using MBTH
A simple visible spectrophotometric method is proposed for the determination of ulipristal acetate present in bulk and tablet formulation. The currently proposed method is established based on MBTHExpand
Insights into the interaction of ulipristal acetate and human serum albumin using multi-spectroscopic methods, molecular docking, and dynamic simulation
TLDR
Results indicated that UPA can stabilize HSA to a certain degree and enhance the flexibility of residues around site I and hydrophobicity around the tryptophan residues declined, whereas its polarity increased. Expand
...
1
2
...

References

SHOWING 1-10 OF 34 REFERENCES
Ulipristal acetate versus leuprolide acetate for uterine fibroids.
TLDR
Both the 5-mg and 10-mg daily doses of ulipristal acetate were noninferior to once-monthly leuprolide acetate in controlling uterine bleeding and were significantly less likely to cause hot flashes. Expand
Long-term treatment of uterine fibroids with ulipristal acetate ☆.
TLDR
Repeated 3-month UPA courses effectively control bleeding and shrink fibroids in patients with symptomatic fibroid problems, and NETA did not affect fibroid volume or endometrial histology. Expand
Long-term medical management of uterine fibroids with ulipristal acetate.
TLDR
The results of this study demonstrate the efficacy and further support the safety profile of repeated intermittent treatment of symptomatic fibroids with ulipristal acetate and pain and QoL showed marked improvements from screening, even during the off-treatment intervals. Expand
Efficacy and safety of repeated use of ulipristal acetate in uterine fibroids.
TLDR
Repeated 12-week courses of daily oral ulipristal acetate (5 and 10 mg) effectively control bleeding and pain, reduce fibroid volume, and restore QoL in patients with symptomatic fibroids. Expand
Safety after extended repeated use of ulipristal acetate for uterine fibroids
TLDR
The results of this study further support the safety profile of extended repeated 3 months treatment of symptomatic fibroids with ulipristal acetate 10 mg/day, with focus on endometrial and laboratory safety parameters. Expand
Role of ethnicity in treating uterine fibroids with ulipristal acetate.
TLDR
Both ethnicities had similar improvement in fibroid symptomatology following UPA treatment, but white women experienced higher amenorrhea rates, while black women had greater fibroid burden at baseline. Expand
Endometrial Morphology After Treatment of Uterine Fibroids With the Selective Progesterone Receptor Modulator, Ulipristal Acetate
TLDR
The morphology of the endometrium after 3 mo of treatment with the SPRM, ulipristal acetate (UPA) is described and it is important that pathologists are aware of the spectrum of changes induced by SPRMs to avoid misdiagnoses of endometrial hyperplasia or polyps. Expand
First series of 18 pregnancies after ulipristal acetate treatment for uterine fibroids.
TLDR
The first series of pregnancies achieved after UPA treatment for fibroids are reported, confirming a sustained long-term effect afterUPA therapy, and the pregnancy rate and live birth rate are measured. Expand
EMAS position statement: management of uterine fibroids.
TLDR
The choice of treatment depends on fibroid size, the underlying symptoms and their severity and the woman's desire for subsequent fertility and pregnancy, as well as efficacy and need for repeated interventions. Expand
Real world data of 1473 patients treated with ulipristal acetate for uterine fibroids: Premya study results.
TLDR
The majority of patients with moderate to severe symptoms of uterine fibroids and undergoing a pre-operative treatment with UPA (Esmya®) do not undergo surgery immediately after treatment cessation, and quality of life and pain are highly improved by Esmya®, treatment. Expand
...
1
2
3
4
...